who should not use a glp 1 GLP-1 Meds: What They Really Do and What They Don't The unknown trajectory of GLP-1

November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors

The board also notes that it already observes patient safety issues in areas where its authority is limited

The global body contouring market is projected to reach $11 billion by 2030, with non-invasive procedures driving much of this growth (Market Research Future)

The reason we say we want it first is once again, if you look at setting the patient up for success, if you want them to be able to last on this program long-term, you want them to start to understand how to eat better because if theyre not eating better, youre setting themselves up for failure